Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2025-10-10

Clinical Trial Update: Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating sequential cabozantinib therapy for advanced renal cell carcinoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Cabometyx (cabozantinib)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: RCC, Renal Cell Carcinoma | Phase 2 | Status: RECRUITING